**Table**

| Sporeforms | n | CT | KT | FEP | CAZ | ATM | LYM | AMK |
|------------|---|----|----|-----|-----|-----|-----|-----|
| All Enterobacterales | 209 | 01.3 | 87.0 | 10.8 | 44.2 | 79.1 | 91.8 | 90.9 |
| K. pneumoniae | 164 | 94.7 | 82.1 | 78.5 | 75.0 | 77.2 | 95.1 | 79.6 |
| E. coli | 170 | 98.2 | 92.9 | 89.4 | 85.9 | 86.3 | 100 | 65.9 |
| P. aeruginosa | 305 | 69.4 | 24.8 | 32.0 | 0.0 | 99.0 | 44.4 | 93.1 |
| Enterobacteriaceae + P. aeruginosa | 1350 | 94.2 | 81.5 | 80.2 | 76.5 | 88.5 | 94.4 | 74.2 |
| CZA/NS | 209 | 77.0 | 35.0 | 43.0 | 40.7 | 25.6 | 0.0 | 32.2 |
| FEP/NS | 209 | 71.6 | 0.0 | 37.0 | 21.0 | 55.4 | 61.5 | 40.5 |
| MEM/NS | 177 | 0.3 | 31.5 | 43.0 | 40.7 | 25.6 | 0.0 | 32.2 |
| PT/NS | 209 | 71.6 | 0.0 | 37.0 | 21.0 | 55.4 | 61.5 | 40.5 |

*Disclosures.* Sibylle Lob, PhD, IHHM (Employee); Pfizer, Inc. (Consultant); Daryl DePestel, PharmD, BCPS-ID, Merck & Co, Inc. (Employee); Katherine Young, MS, Merck & Co, Inc. (Employee); Sherwood, Inc. (Employee); Daniel F. Sahin, PhD, IHHM (Employee); Pfizer, Inc. (Consultant); Shionogi & Co., Ltd. (Independent Contractor)

**Conclusion.** With its broad coverage of Enterobacterales and *P. aeruginosa*, C/T can provide an important empiric therapy option for patients with LRTI in the US.

**Disclosures.** Sibylle Lob, PhD, IHHM (Employee); Pfizer, Inc. (Consultant); Daryl DePestel, PharmD, BCPS-ID, Merck & Co, Inc. (Employee); Katherine Young, MS, Merck & Co, Inc. (Employee); Sherwood, Inc. (Employee); Daniel F. Sahin, PhD, IHHM (Employee); Pfizer, Inc. (Consultant); Shionogi & Co., Ltd. (Independent Contractor)

**1588. Activity of Imipenem/Relebactam Against Clinical Isolates of *P. aeruginosa* and *K. pneumoniae* Collected in Asia/Pacific Countries — SMART 2016-2018**

Sibylle Lob, PhD; Krystyna Karmieczek, PhD; Wei-Ting Chen, MD; Tsz Kin Khan, PhD; Mary Motyl, PhD; Sibylle Lob, PhD; Mary F.Sahin, PhD; IHMA Inc.; Schaumburg, IL; Merck, Sharp & Dohme, Taiwan, Taipei, Taipei, Taiwan; Merck, Sharp & Dohme, Hong Kong, Hong Kong, Not Applicable, Hong Kong; Merck & Co, Inc., Kenilworth, NJ; Merck & Co, Inc., Kenilworth, NJ

**Session:** P-71. Treatment of Antimicrobial Resistant Infections

**Background.** Relebactam (REL) inhibits class A and C beta-lactamases and was approved in the USA in combination with imipenem (IMI) and cilastatin for the treatment of complicated intrabdominal and urinary tract infections. We evaluated the activity of IMI/REL against clinical isolates collected in Asia/Pacific as part of the global SMART surveillance program.

**Methods.** In 2016-2018, 56 clinical laboratories each collected up to 250 consecutive, aerobic and facultative gram-negative pathogens from various infection sources per year. Susceptibility was determined using CLSI broth microdilution and CLSI breakpoints. IMI-nonsusceptible isolates (except from India) were screened for beta-lactamases genes.

**Results.** Among 5501 *K. pneumoniae* and 4362 *P. aeruginosa* isolates, 46.6% and 65.3%, respectively, were collected from patients with lower respiratory tract infections, 25.6% and 17.1% from intrabdominal infections, 19.9% and 13.9% from urinary tract infections, and 7.2% and 2.9% from bloodstream infections. No isolates were meropenem susceptible. Tigecycline was the most active comparator with 98.5% 

**Conclusion.** These results demonstrate MVB has potent activity against the internationally disseminated, KPN, with resistance to 
P. aeruginosa. No isolates were meropenem susceptible. Tigecycline was the most active comparator with 98.5% susceptibility.

**Disclosures.** Timothy B. Doyle, Allergan (Research Grant or Support) Allergan (Research Grant or Support) Cipla Ltd. (Research Grant or Support) Melinta Therapeutics, Inc. (Research Grant or Support) Pfizer (Research Grant or Support) Qpex Biopharma (Research Grant or Support) Jennifer M. Streit, BS, A. Menarini Industrie Farmaceutiche Riunite S.R.L. (Research Grant or Support) Pfizer, Inc. (Consultant) Wei-Ting Chen, MD, Merck, Sharp & Dohme, Taiwan (Employee); Tsz Kin Khan, PhD, Merck, Sharp & Dohme, Hong Kong (Employee); Katherine Young, MS, Merck & Co, Inc. (Employee); Sherwood, Inc. (Employee); Daniel F. Sahin, PhD, IHHM (Employee); Pfizer, Inc. (Consultant); Shionogi & Co., Ltd. (Independent Contractor)